Meta-analysis of 330 PCOS women shows liraglutide improves BMI, insulin resistance, and menstrual frequency while lowering male hormones, addressing both metabolic and reproductive aspects of the syndrome.
Large effect on menstrual frequency (g=1.76)Liraglutide significantly increased menstrual frequency in overweight/obese PCOS women compared to controls, alongside improvements in BMI and insulin resistance
What the researchers found
In a meta-analysis of 7 RCTs (330 women with PCOS), liraglutide significantly improved both metabolic and reproductive outcomes: it increased menstrual frequency (g=1.76), reduced BMI (g=-0.52), improved insulin resistance (HOMA-IR g=-0.52), lowered luteinizing hormone and free androgen index, and modestly increased sex hormone-binding globulin. Adverse events were mainly mild GI symptoms. Ovulation and pregnancy outcomes could not be pooled due to insufficient data from the included trials.
Why it matters
PCOS affects 6-12% of reproductive-age women and causes both metabolic problems (insulin resistance, weight gain) and reproductive dysfunction (irregular periods, infertility). This meta-analysis provides the first pooled evidence that liraglutide addresses both dimensions simultaneously — improving insulin sensitivity and weight while also restoring menstrual regularity and improving hormonal balance.
The numbers in context
7 RCTs · n=330 · Menstrual frequency: g=1.76, P<0.05 · BMI: g=-0.52 · HOMA-IR: g=-0.52 · LH ↓ · Free androgen index ↓ · SHBG ↑
How the study worked
Systematic review and meta-analysis of RCTs comparing liraglutide (alone or combined) to placebo, metformin, or other active treatments in overweight/obese PCOS women. Six databases searched through May 2025. Random-effects model used. Results expressed as Hedges' g or odds ratios with 95% CIs.
Who was studied
330 overweight or obese women with polycystic ovary syndrome from 7 randomized controlled trials
What this study cannot tell us
Small total sample of only 330 women across 7 trials. High heterogeneity for menstrual frequency outcome. Ovulation and pregnancy rates could not be analyzed due to insufficient reporting. Most studies likely used the 1.8 mg diabetes dose rather than the 3.0 mg weight loss dose. No long-term follow-up data.
How to read the evidence
This is a systematic review and meta-analysis of 7 randomized controlled trials, representing a strong study design. However, the total sample of 330 women is small, heterogeneity was high for the key reproductive outcome, and critical endpoints like pregnancy rates couldn't be analyzed.
When this study was published
Published in 2026 with literature search through May 2025, this is the most current meta-analysis of liraglutide in PCOS. As newer GLP-1 drugs gain traction, future analyses will likely include semaglutide and tirzepatide data.
The bigger picture
GLP-1 drugs are rapidly expanding beyond diabetes and obesity into adjacent conditions where metabolic dysfunction drives disease. PCOS is a prime example — insulin resistance fuels the hormonal imbalance that causes irregular periods and infertility. This meta-analysis adds to growing evidence that GLP-1 agonists could become a treatment for PCOS, particularly as newer, more potent agents like semaglutide and tirzepatide become available.
Questions still open
- Would semaglutide or tirzepatide show even stronger effects in PCOS given their greater weight loss efficacy compared to liraglutide?
- Does liraglutide actually improve ovulation and pregnancy rates in PCOS, or only menstrual frequency as a surrogate marker?
- Should GLP-1 agonists be considered first-line therapy for overweight PCOS women, potentially replacing metformin?
Common questions
Can GLP-1 drugs like liraglutide help with PCOS?
How does liraglutide compare to metformin for PCOS?
Read the original research
Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.
Diabetes, obesity & metabolism
Citation
Lu, Yu-Ting; Chang, Po-Han; Chen, Hsuan-Ju; Hsueh, Ya-Wen; Chang, Chia-Wei; Hsu, Hsi-Chen; Yang, Tung-Chuan; Lin, Wu-Chou; Chang, Hsun-Ming. (2026). Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70452